Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 64 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback